Press Releases
March 2012 - HUYA BIOSCIENCE INTERNATIONAL ANNOUNCES NEW PARTNERSHIP WITH A HIGH PROFILE PHARMACEUTICAL LAB AT SHANGHAI’S PRESTIGIOUS FUDAN UNIVERSITY
San Diego, CA – March 20, 2012 - HUYA Bioscience International announced today a critical strategic partnership with one of China’s preeminent pharmacological researchers, Prof. Deyong Ye of Fudan University’s School of Pharmacy. HUYA is an international leader in supporting the global development of China’s pharmaceutical
innovations. Their new partnership with Fudan University will focus on specific innovations coming out of Prof. Deyong Ye’s lab that could meet critical global pharmaceutical needs.
Read Full Press Release
Jan 2012 - HUYA BIOSCIENCE INTERNATIONAL ANNOUNCES STRATEGIC PARTNERSHIP WITH THE TIANJIN INSTITUTE OF PHARMACEUTICAL RESEARCH
San Diego, CA – Jan 18, 2012 - HUYA Bioscience International today announced a strategic partnership agreement with the Tianjin Institute of Pharmaceutical Research (TIPR). HUYA is a leader in globalizing China’s biopharmaceutical innovations and TIPR is one of the leading pharmaceutical research institutes in China. The collaborative agreement will combine both parties‘ strengths in promoting the advancement of China’s drug innovations.
Read Full Press Release
Nov 2011 - HUYA BIOSCIENCE INTERNATIONAL BUILDS LONG-TERM RELATIONALSHIP WITH SHENZHEN POLYTECHNIC SCHOOL OF APPLIED CHEMISTRY AND BIOTECHNOLOGY
San Diego, CA – Nov 8, 2011 - HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic partnership with the Shenzhen Polytechnic School of Applied Chemistry and Biotechnology (SPSACBT). The alliance with HUYA will assist the school in accelerating the development of novel drugs, discovered from research laboratories within the school, to international standards.
Read Full Press Release
Oct 2011 - HUYA BIOSCIENCE INTERNATIONAL AND TIANJIN INTERNATIONAL JOINT ACADEMY OF BIOTECHNOLOGY AND MEDICINE FORM ALLIANCE
San Diego, CA – Oct 18, 2011 - HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic alliance with the Tianjin International Joint Academy of Biotechnology and Medicine (TJAB). The alliance will unite the strength and resources of both parties to accelerate the development of China’s biomedical innovation and industrialization.
Read Full Press Release
Sept 2011 - HUYA BIOSCIENCE INTERNATIONAL FORMS ALLIANCE WITH ZHEJIANG CHINESE MEDICAL UNIVERSITY LIFE COLLEGE
San Diego, CA – Sept 8, 2011 - HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic partnership with the Zhejiang Chinese Medical University Life Science College. The collaboration agreement will accelerate the global drug development of China’s novel Traditional Chinese Medicines (TCM).
Read Full Press Release
July 2011 - HUYA BIOSCIENCE INTERNATIONAL ENGAGES IN PARTNERSHIP WITH
LIAONING (BENXI) BIO-PHARMACEUTICAL INDUSTRY BASE
San Diego, CA – July 8, 2011 - HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic partnership with the Liaoning (Benxi) Bio-Pharmaceutical Industry Base. The collaboration agreement will combine both parties’ strength in aiding the advancement of China’s drug innovation platform.
Read Full Press Release
March 2011 - HUYA BIOSCIENCE AND WUHAN BIOLAKE FORM ALLIANCE TO HELP ACCELERATE CHINA'S BIO-INDUSTRY DEVELOPMENT
San Diego, CA – March 8, 2011 - HUYA Bioscience International, a leader in globalizing China's pharmaceutical innovations, today announced a strategic alliance with Wuhan National Bio-industry Base, also known as Biolake. The alliance is expected to combine both parties' resources to accelerate the development of pharmaceutical discoveries from China.
Read Full Press Release
September 2010 - HUYA BIOSCIENCE AND QUINTILES ANNOUNCE PARTNERSHIP
FOR PHASE I DEVELOPMENT OF NEW CANCER THERAPY
San Diego, CA & Research Triangle Park, NC – September 28, 2010 - HUYA Bioscience International (HUYA), the leader in U.S.-China pharmaceutical co-development, and Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced an agreement to co-develop a new cancer drug, HBI-8000, sourced in China by HUYA.
Read Full Press Release
August 2010 - HUYA BIOSCIENCE ESTABLISHES STRATEGIC PARTNERSHIP WITH SUN YAT-SEN UNIVERSITY’S SCHOOL OF PHARMACEUTICAL SCIENCES
San Diego, CA – August 30, 2010 - HUYA Bioscience International, a company at the forefront of globalizing China’s biopharmaceutical innovations, today announced a strategic partnership with the School of Pharmaceutical Sciences at Sun Yat-sen University (SYSU). The collaborative agreement expands HUYA’s foothold in Southern China, aiming to accelerate the development of novel drugs arising from the school’s research efforts.
Read Full Press Release
June 2010 - HUYA BIOSCIENCE INTERNATIONAL AND CHINA MEDICAL CITY FORGE ALLIANCE TO HELP DEVELOP CHINA’S PHARMACEUTICAL INDUSTRY
San Diego, CA – June 28, 2010 - HUYA Bioscience International, a leader in globalizing China’s pharmaceutical innovations, today announced a strategic partnership with the Taizhou National Medical Hi-tech Development Zone, also known as “China Medical City” (CMC). The alliance will combine both parties’ strengths in pharmaceutical product R&D and commercialization in order to promote China’s pharmaceutical-biotech industry to the worldclass
level.
Read Full Press Release
May 2010 - HUYA BIOSCIENCE INTERNATIONAL STRENGTHENS R&D LEADERSHIP IN TRADITIONAL CHINESE MEDICINE WITH THE SCHOOL OF CHINESE MATERIA MEDICA, BEIJING UNIVERSITY OF CHINESE MEDICINE
San Diego, CA – May 28, 2010 - HUYA Bioscience International, a leader in
globalizing China’s biopharmaceutical innovation, today announced a strategic partnership with
the School of Chinese Materia Medica of the Beijing University of Chinese Medicine (BUCM).
As one of a series of collaborations that HUYA has established with China’s leading research
and development institutions, the agreement demonstrates HUYA’s visionary commitment to
enabling and accelerating the global development and commercialization of novel
biopharmaceutical products originating in China.
Read Full Press Release
November 2009 - HUYA BIOSCIENCE INTERNATIONAL ESTABLISHES STRATEGIC PARTNERSHIP WITH SCHOOL OF MEDICINE AND PHARMACY, OCEAN UNIVERSITY OF CHINA
San Diego, CA – November 8, 2009 - HUYA Bioscience International, a leader in globalizing China’s biopharmaceutical innovation, today announced a strategic partnership with the School of Medicine and Pharmacy, Ocean University of China. The agreement is another in a series of collaborations that HUYA has established with China’s leading research and development institutions to enable and accelerate the global development and commercialization of novel biopharmaceutical product opportunities originating in China.
Read Full Press Release
May 2009 - SOLVAY PHARMACEUTICALS ANNOUNCES STRATEGIC PARTNERSHIP WITH HUYA TO ACCESS NEW DRUG CANDIDATES FROM CHINA
Brussels, 18 May 2009 - Solvay Pharmaceuticals announces it has signed an agreement with HUYA Bioscience International, a company specialized in enabling and accelerating global codevelopment of novel biopharmaceutical product opportunities originating in China.
Read Full Press Release
21 April 2009 - HUYA BIOSCIENCE ANNOUNCES STRATEGIC ALLIANCE WITH ABBOTT ON DRUG AND BIOMARKER DEVELOPMENT CANDIDATES FROM CHINA
Collaboration will leverage HUYA's growing Chinese bioscience network
San Diego, CA, April 21, 2009 – HUYA Bioscience International, a leader in US/China pharmaceutical co-development, today announced an agreement with Abbott to identify and pursue proprietary preclinical and clinical drug candidates that originate in China.
Read Full Press Release
18 February 2009 - HUYA BIOSCIENCE INT’L ANNOUNCES COLLABORATION AGREEMENT WITH THE BEIJING INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF MEDICAL SCIENCES AND PEKING UNION MEDICAL COLLEGE
San Diego, February 18 2009 - HUYA Bioscience International, the leader in US/China pharmaceutical co-development, today announced a partnership agreement with the Beijing Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College (collectively – The Beijing Institute of Materia Medica, BIMM).
Read Full Press Release
15 December 2008 - HUYA BIOSCIENCE ANNOUNCES AGREEMENT TO PROVIDE SCHERING- PLOUGH WITH DRUG DEVELOPMENT CANDIDATES FROM CHINA
Schering-Plough has selected HUYA to identify and present to Schering-Plough on an exclusive basis proprietary lead, preclinical and clinical drug candidates in specific therapeutic areas that originate in China.
Read Full Press Release
14 April 2008 - HUYA BIOSCIENCE INT’L ANNOUNCES FIRST PRE-IND OUTCOME FOR A DEVELOPMENT STAGE COMPOUND SOURCED FROM CHINA – HBI-8000, PROMISING NEW CANCER COMPOUND
FDA feedback validates HUYA’s Integrated Co-Development Model for China-sourced Drug Candidates
Read Full Press Release
3 March 2008 - HUYA BIOSCIENCE INT’L ANNOUNCES WORLD-CLASS CLINICAL ADVISORY TEAM FOR NEW ANTI-ARRHYTHMIC COMPOUND SOURCED FROM CHINA
Team includes Peter Kowey, pioneer of anti-arrhythmic drugs/devices in U.S., and Eric Topol, one of top 10 cited biomedical researchers over past decade
Read Full Press Release
3 March 2008 - HUYA BIOSCIENCE INT’L ANNOUNCES CLINICAL TRIAL MILESTONES IN CHINA FOR PROMISING NEW ANTI-ARRHYTHMIC COMPOUND; DATA SUPPORTS DESIRABLE SAFETY PROFILE
Progress validates HUYA’s innovative U.S./China pharmaceutical co-development model
Read Full Press Release
2 October 2007 - HUYA BIOSCIENCE INTERNATIONAL LICENSES CLINICAL STAGE ANTI-ARRHYTHMIC COMPOUND FROM THE SHANGHAI INSTITUTE OF MATERIA MEDICA
HUYA Bioscience International (HUYA), a rapidly expanding biopharmaceutical company focused on the development of key disease-fighting drugs sourced from China, announced today that it has licensed a novel clinical stage anti-arrhythmic compound from the prestigious Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences.
Read Full Press Release
24 May 2007 - HUYA BIOSCIENCE INTERNATIONAL AND CHIPSCREEN BIOSCIENCES INITIATE A PHASE I CLINICAL CANCER TRIAL
HUYA Bioscience International, LLC and Chipscreen Biosciences Ltd. announced today that a Phase I clinical trial has been initiated in China with the compound Chidamide (CS055) /HBI-8000, an investigational cancer compound. HUYA holds exclusive rights to the compound (HBI-8000) worldwide outside of China, while Chipscreen maintains rights in China. The Phase I clinical trial is designed to assess the safety, tolerability and pharmacokinetics of the compound.
Read Full Press Release
6 March 2007 - HUYA BIOSCIENCE LICENSES CHIDAMIDE CANCER COMPOUND FROM CHIPSCREEN BIOSCIENCES
HUYA Bioscience International, LLC, announced today that it has exclusively licensed worldwide rights outside China to the cancer compound chidamide from Shenzhen Chipscreen Biosciences Ltd. Chidamide, is an investigational cancer compound currently approved to initiate a Phase I clinical trial in China.
Read Full Press Release
9 January 2007 - ORGANON PARTNERS WITH HUYA TO IDENTIFY AND DEVELOP CHINESE BIOPHARMACEUTICALS COLLABORATION LOOKS FOR OPPORTUNITIES TO EXPAND THE ORGANON BIOTECH RESEARCH PROGRAMS AND FACILITATE LINKS WITH CHINA'S BIOTECH INDUSTRY
Read Full Press Release